Jim Demarest, Ph.D., Scientific Consultant and John C. Pottage, Jr., M.D., Lead Scientific Consultant at the INTREPID Alliance presented findings at the American Society of Tropical Medicine & Hygiene (ASTMH) 2025 Annual Meeting that map current antiviral development activity for vector- and contact-transmitted viruses. The analysis reveals significant unmet needs across preclinical and clinical pipelines.
The INTREPID Alliance presented data from its latest Antiviral Clinical and Preclinical Development Landscape at the American Society of Tropical Medicine and Hygiene (ASTMH) 2025 Annual Meeting, November 9-13, 2025, in Toronto, Canada.
Open-access resource includes Registry of Antiviral Compound Libraries to help catalyze drug discovery for priority viruses of pandemic and endemic concern
One of the most critical initiatives we can do to be better prepared against viral disease outbreaks that could become the next pandemic, is to build a broad and deep pipeline of vaccines, therapeutics and diagnostic products. This will require collaborative R&D spanning the public and private sectors.
Writing in the Clinical Infectious Diseases journal, INTREPID Alliance leaders make the case that small-molecule antivirals are indispensable tools for rapid, scalable, and equitable responses to health security and epidemic and pandemic threats. However, pipeline gaps threaten our ability to provide effective patient care and public health strategies, requiring urgent investment and coordination to strengthen antiviral R&D and ensure future preparedness.
James Anderson, Chair of the INTREPID Alliance and Executive Director of Global Health at IFPMA, shares why antivirals are critical to pandemic preparedness, lessons from COVID-19, and how public–private partnerships can close gaps in the antiviral pipeline to better protect against future viral threats.
The COVID-19 pandemic sent the world into a tailspin, raising ongoing concerns about biosecurity, a subject that encompassed the better part of the morning June 16, the first day of the Biotechnology Innovation Organization’s annual conference in Boston.
This INTREPID-hosted panel at the BIO International Convention brings together voices from across the global public and private R&D and investment communities to discuss what can be done from within the biotech ecosystem today, to ensure that we aren’t left unprepared to treat the next pandemic tomorrow.
Global antiviral R&D is slowing when the world can least afford it, new analysis shows
This article presents a recommended Antiviral Target Compound Profile (TCP) developed by the INTREPID Alliance. The TCP is designed to accelerate the development of and facilitate global access to antivirals targeting pandemic-potential pathogens.
NIAID seeks proposals to advance the research and development of innovative candidate therapeutics, vaccines, and diagnostics for antimicrobial-resistant (AMR) pathogens and viruses with pandemic potential.
Renowned experts in virology, immunology, and drug development will help guide INTREPID’s efforts to accelerate breakthrough antiviral therapies for emerging viral pandemic agents
Current mpox outbreak underscores gaps in access to medical countermeasures to help mitigate the severity of future outbreaks
Detailed scientific analysis of antiviral pipeline identifies most promising clinical compounds aligned with 100 Days Mission global preparedness recommendations
The Chair of the INTREPID Alliance’s Scientific Advisory Board, Dr. Ruxandra Draghia-Akli, delivered remarks at the opening session of the International Arbovirus Summit hosted by GISAID and the Ministries of Health for Brazil and Indonesia.
Global landscape analysis identifies strengths and gaps in R&D pipeline to inform international pandemic preparedness efforts
As leaders and health experts from across the world gather in New York for the UN General Assembly, they will be considering three issues that are critical to the future of global health and global health security.
The INTREPID Alliance has abandoned its fundraising plans, but not its mission to expedite antiviral development for future pandemics.
An alliance of seven R&D-based pharma firms is putting collaboration and partnerships at the center of the search for new antivirals against emerging pathogens.
Seven innovative pharmaceutical companies have established the INTREPID Alliance, with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics.